Andre Daniels

Andre Daniels has a wealth of experience in the pharmaceutical and medical research industry. Andre began their career at Pfizer in 1997, where they served as the Therapeutic Area Safety Head for Endocrinology and Cardiology. In 2002, they joined Gilead Sciences as the Director of Medical Assessment and Risk Management. Andre then moved on to Amgen in 2005, holding the position of Executive Director for Amgen Global Safety until 2014. Andre then joined Allergan as VP Medical Safety before transitioning to Astellas Pharma US in 2016 as the Global Senior Medical Director. In 2019, Andre took on leadership roles at Comprehensive Medical Safety Consulting and FOMAT Medical Research, serving as Chief Executive Officer and Chief Safety Officer respectively.

Andre Daniels has a degree in Internal Medicine from the College Of Medicine in South Africa, with the degree of FCP (SA). Additionally, they have a degree in Internal Medicine from the Royal Australasian College of Physicians, with the degree of FRACP. Andre also holds a degree in Medicine and Surgery (MBChB) from the University of Cape Town. Lastly, Andre has a degree in Clinical epidemiology and Biostatistics (MMedSci) from the University of Newcastle.